Use of cordyceps sinensis in preparation of Anti-radiation injury health product or drug

Abstract

Disclosed is use of Cordyceps sinensis in the preparation of a health product or drug for preventing and / or treating radiation injury, particularly in the preparation of a health product or drug for preventing and / or treating intestinal radiation injury caused by ionizing radiation. Specifically, Cordyceps sinensis can significantly ameliorate symptoms caused by intestinal radiation injury, such as weight loss, shortened colon length, elevated ROS content in blood and / or small intestine, elevated inflammation levels in blood and / or small intestine, and small intestine tissue injury.

Description

Uses of Cordyceps sinensis in the preparation of anti-radiation damage health products or medicines Technical Field

[0001] This invention belongs to the field of biomedicine technology. Specifically, this invention relates to the application of Cordyceps sinensis in the preparation of anti-radiation damage health products or medicines. Background Technology

[0002] Ionizing radiation (IR) can have significant effects on the bone marrow hematopoietic system, gastrointestinal tract, and nervous system. The intestines, being rapidly regenerating tissue, are particularly sensitive to ionizing radiation. Systemic radiation damage (such as that caused by nuclear explosions or accidents) and localized radiotherapy for tumors in the abdominal and pelvic cavities can all cause damage to intestinal structure and function. Acute intestinal syndrome is a leading cause of death within the first week after exposure to high doses of radiation. Rapid and destructive damage to intestinal epithelial cells primarily leads to intestinal electrolyte imbalance, malabsorption, and translocation of intestinal pathogens, ultimately resulting in loss of intestinal function and a significantly increased risk of death.

[0003] In clinical practice, radiation-induced intestinal radiation injury is a common complication of radiotherapy for abdominal and pelvic tumors, severely limiting the intensity and efficacy of radiotherapy plans. Currently, there are no effective prevention and treatment methods for intestinal radiation injury, both domestically and internationally. Therefore, finding effective health products or drugs for the prevention and treatment of intestinal radiation injury is of great significance. In recent years, a series of compounds with radiation-protective effects, including aminothiols, natural antioxidants, hormone-based health products or drugs, and biological macromolecular preparations, have been researched and developed, including amifostine, cysteine, estrogen, and vitamins. However, most of these compounds do not have clear efficacy or excellent performance. To date, amifostine is the only FDA-approved clinical radioprotective agent for head and neck cancer patients, used to reduce the incidence of moderate to severe xerostomia. The main mechanism of action of amifostine is that, in the presence of a single-bonded SH group, its metabolite (WR1065) can scavenge oxygen free radicals generated by ionizing radiation, thereby preventing oxygen free radicals from damaging intracellular macromolecules. Nevertheless, because the effective dose of amifostine is close to the minimum toxic dose, increasing the dose may lead to significant adverse reactions and limit its widespread use.

[0004] Cordyceps sinensis is a rare, naturally occurring traditional Chinese medicine. Besides common components such as sugar, fat, and crude fiber, it also contains active ingredients like mannitol, ergosterol, adenosine, cordycepic acid, cordycepin, and vitamin B12. Its tonic and therapeutic effects surpass those of ginseng and deer antler. However, natural Cordyceps sinensis has a long growth period, is distributed in high-altitude alpine meadows, is scarce, difficult to harvest, and very expensive.

[0005] Hangzhou Sino-American East China Pharmaceutical Co., Ltd. has exclusively produced a Class I new drug in China, "Bailing Capsules" (containing fermented Cordyceps sinensis mycelium powder CS-C-Q80), using artificial fermentation methods. This drug is listed in the Pharmacopoeia of the People's Republic of China. The Cordyceps sinensis mycelium powder (CS-C-Q80) is a dried powder of mycelium obtained from the deep liquid fermentation of *Hirsutella sinensis*. Bailing Capsules can be used for cough, asthma, hemoptysis, lower back pain, facial puffiness, and frequent urination at night caused by deficiency of both lung and kidney; it is also used as an adjunct treatment for chronic bronchitis and chronic renal insufficiency. Summary of the Invention

[0006] In order to overcome the above-mentioned technical problems existing in the field, the purpose of this invention is to provide the medicinal use of Cordyceps sinensis as a health product or medicine for anti-radiation damage, and to provide an effective health product or medicine strategy for the field.

[0007] The present invention achieves the above-mentioned objective by adopting the following technical solution: On the one hand, the present invention provides the use of Cordyceps sinensis in the preparation of products for the prevention and / or treatment of radiation damage.

[0008] Furthermore, the radiation damage is caused by ionizing radiation.

[0009] Furthermore, the ionizing radiation is ionizing radiation generated by tumor radiotherapy.

[0010] Furthermore, the ionizing radiation is gamma-ray radiation.

[0011] Furthermore, the radiation damage is intestinal type radiation damage.

[0012] Furthermore, the intestinal radiation injury has one or more of the following symptoms: weight loss, shortened colon length, elevated blood and / or small intestinal ROS levels, elevated blood and / or small intestinal inflammation levels, and small intestinal tissue damage.

[0013] Furthermore, the elevated levels of inflammation in the blood and / or small intestine include increased levels of inflammatory immune factors.

[0014] Furthermore, the inflammatory immune factors are IL-6 and / or TNF-α.

[0015] The product in question is a health supplement or a medicine.

[0016] In another aspect, the present invention also provides the use of 4g to 8g (e.g., 4g, 5g, 6g, 7g or 8g) unit dose of Cordyceps sinensis in products for the prevention and / or treatment of radiation damage.

[0017] Furthermore, the unit dose of Cordyceps sinensis is administered once daily.

[0018] Furthermore, the radiation damage is caused by ionizing radiation.

[0019] Furthermore, the ionizing radiation is ionizing radiation generated by tumor radiotherapy.

[0020] Furthermore, the ionizing radiation is gamma-ray radiation.

[0021] Furthermore, the radiation damage is intestinal type radiation damage.

[0022] Furthermore, the intestinal radiation injury has one or more of the following symptoms: weight loss, shortened colon length, elevated blood and / or small intestinal ROS levels, elevated blood and / or small intestinal inflammation levels, and small intestinal tissue damage.

[0023] Furthermore, the elevated levels of inflammation in the blood and / or small intestine include increased expression of inflammatory immune factors.

[0024] Furthermore, the inflammatory immune factors are IL-6 and / or TNF-α.

[0025] The product in question is a health supplement or a medicine.

[0026] For any of the uses described above, Cordyceps sinensis is obtained by artificial fermentation of the asexual form of Cordyceps sinensis fungus.

[0027] Furthermore, the asexual fungus of Cordyceps sinensis is Hirsutella sinensis.

[0028] Furthermore, the Cordyceps sinensis mentioned is Bailin Capsules.

[0029] Furthermore, 4g to 8g unit dose of Cordyceps sinensis refers to 4g to 8g of Cordyceps sinensis mycelium powder prepared into unit dose form, including but not limited to tablets, capsules and / or pills.

[0030] In another aspect, the present invention also provides a method for preventing and / or treating radiation damage, the method comprising administering an effective amount of Cordyceps sinensis to a subject in need.

[0031] Furthermore, the radiation damage is caused by ionizing radiation.

[0032] Furthermore, the ionizing radiation is ionizing radiation generated by tumor radiotherapy.

[0033] Furthermore, the ionizing radiation is gamma-ray radiation.

[0034] Furthermore, the radiation damage is intestinal type radiation damage.

[0035] Furthermore, the intestinal radiation injury has one or more of the following symptoms: weight loss, shortened colon length, elevated blood and / or small intestinal ROS levels, elevated blood and / or small intestinal inflammation levels, and small intestinal tissue damage.

[0036] Furthermore, the elevated levels of inflammation in the blood and / or small intestine include increased levels of inflammatory immune factors.

[0037] Furthermore, the inflammatory immune factors are IL-6 and / or TNF-α.

[0038] Furthermore, the method includes administering a unit dose of 4g to 8g of Cordyceps sinensis to the subject in need.

[0039] Furthermore, the unit dose of Cordyceps sinensis is administered once daily.

[0040] The administration method can be gastrointestinal (e.g., oral) or non-gastrointestinal (e.g., intravenous, intramuscular, subcutaneous, intradermal, intra-organ, intranasal, intraocular, intravenous, intracerebral, intrathecal, transdermal, rectal, etc.) routes.

[0041] Compared to existing technologies, this invention offers several advantages: Firstly, it discovers that Cordyceps sinensis can significantly improve symptoms caused by intestinal radiation injury, such as weight loss, shortened colon length, increased ROS levels in the blood and / or small intestine, increased inflammation levels in the blood and / or small intestine, and small intestinal tissue damage. It can serve as a preventative health product or drug for radiation injury, particularly intestinal radiation injury, addressing the current lack of truly effective health products or drugs for the clinical treatment of intestinal radiation injury. Furthermore, it provides new ideas and strategies for developing anti-radiation damage health products or drugs, possessing significant scientific and clinical application value. Attached Figure Description

[0042] Figure 1. Effect of Cordyceps sinensis fermentation powder on body weight of mice with intestinal radiation injury.

[0043] Figure 2. Effects of Cordyceps sinensis fermented mycelium powder on the colon of mice with intestinal radiation injury.

[0044] Figure 3. Effect of Cordyceps sinensis fermentation powder on blood ROS content in mice with intestinal radiation injury.

[0045] Figure 4. Effect of Cordyceps sinensis fermented mycelium powder on ROS content in the small intestine of mice with intestinal radiation injury.

[0046] Figure 5. Effect of Cordyceps sinensis fermented mycelium powder on blood IL-6 levels in mice with intestinal radiation injury.

[0047] Figure 6. Effect of Cordyceps sinensis fermentation powder on IL-6 content in the small intestine of mice with intestinal radiation injury.

[0048] Figure 7. Effect of Cordyceps sinensis fermented mycelium powder on blood TNF-α levels in mice with intestinal radiation injury.

[0049] Figure 8. Effect of Cordyceps sinensis fermentation powder on TNF-α content in the small intestine of mice with intestinal radiation injury.

[0050] Figure 9. Effects of Cordyceps sinensis fermented mycelium powder on the small intestinal tissue structure of mice with intestinal radiation injury. Detailed Implementation

[0051] The embodiments of the present invention are described in detail below. These embodiments are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0052] According to an embodiment of the present invention, Cordyceps sinensis is provided in the form of fermented Cordyceps sinensis mycelium powder.

[0053] In this text, the term "fermented Cordyceps sinensis mycelial powder" refers to the dried powder obtained by liquid fermentation of the asexual generation of the fungus *Cordyceps sinensis* (family Clavicipitaceae) isolated from the fruiting body of *Cordyceps sinensis*. In some contexts, it is equivalent to "fermented Cordyceps sinensis." For example, fermented Cordyceps sinensis mycelial powder can be the dried powder obtained by liquid fermentation of the asexual generation of the fungus *Cordyceps sinensis* (family Clavicipitaceae) isolated from fresh *Cordyceps sinensis* in Qinghai, or the dried powder obtained by liquid fermentation of the asexual generation of *Cordyceps sinensis* (family Clavicipitaceae) isolated from the fruiting body of *Cordyceps sinensis* in Tibet. In some embodiments, the fermented Cordyceps sinensis mycelial powder is derived from Bailin capsules, and its fingerprint profile matches that of wild Cordyceps sinensis, which is rich in nucleosides, sugar alcohols, sterols, and amino acids. Therefore, in terms of medicinal value, the two have similar effects. Because wild Cordyceps sinensis has a high heavy metal content, industrial fermentation processes are used to precisely control reaction conditions. This ensures that the metal content in the fermented Cordyceps sinensis powder meets safety standards and that the quality of each batch is stable and controllable, eliminating consumer concerns. At the same time, its price is far lower than that of wild Cordyceps sinensis.

[0054] In this article, intestinal radiation injury is also referred to as radiation-induced intestinal injury (RIII). Colorectal cancer is one of the most common malignant tumors of the digestive system, and its incidence and mortality rates have been increasing year by year in recent years. The latest cancer statistics released by the National Cancer Center in 2024 show that the overall incidence of colorectal cancer in my country ranks second among malignant tumors. Surgery remains the main treatment for colorectal cancer, but for advanced colorectal cancer (especially advanced rectal cancer), surgery alone may not achieve complete resection. Radiation therapy (RT), as an important component of neoadjuvant therapy, is one of the most important treatment methods for pelvic malignant tumors. Although radiotherapy technology has continuously improved, damage to normal tissues by radiation cannot be avoided. Because intestinal tissue renews itself quickly and is sensitive to ionizing radiation, intestinal radiation injury is easily caused after radiotherapy. Statistics show that the incidence of intestinal radiation injury of varying degrees after radiotherapy is 2%-17%. The main clinical manifestations of intestinal radiation injury are diarrhea, abdominal pain, and gastrointestinal bleeding. However, severe cases can lead to massive gastrointestinal bleeding, obstruction, perforation, and fistula, significantly impacting patients' quality of life and even threatening their lives. Simultaneously, due to these complications, some cancer patients are forced to reduce their radiotherapy dose or discontinue radiotherapy, thus reducing the effectiveness of cancer treatment. Given the increasing incidence of abdominal and pelvic malignancies such as colorectal cancer in recent years, radiotherapy techniques are being used more widely, and the incidence of RIII (reduced risk factor) is also showing an increasing trend.

[0055] The term "treatment" as used in this invention refers to exposing a subject to (e.g., administering medication) the Cordyceps sinensis described in this invention after contracting a disease, thereby alleviating the symptoms of the disease compared to when not exposed, without implying the necessity of completely suppressing the symptoms. Contracting a disease means the appearance of disease symptoms in the body.

[0056] The "prevention" mentioned in this invention refers to reducing the probability of contracting a disease and / or alleviating the symptoms after contracting a disease by exposing the subject to the Cordyceps sinensis described in this invention before contracting the disease, compared to not exposing the subject to the disease. It does not mean that it is necessary to completely suppress the disease.

[0057] The term "effective amount" as used in this invention refers to the amount or dose of Cordyceps sinensis of this invention that provides the desired treatment or prevention after being administered to a subject in one or more doses.

[0058] The "subject" described in this invention can be a human or a non-human animal, or a cell, tissue, or organ of a human or non-human animal. The non-human animal can be a non-human mammal, including but not limited to wild animals, zoo animals, commercially valuable animals, pets, laboratory animals, etc. Preferably, the non-human mammal includes, but is not limited to, pigs, cattle, sheep, horses, donkeys, foxes, raccoon dogs, minks, camels, dogs, cats, rabbits, mice (e.g., rats, mice, guinea pigs, hamsters, gerbils, chinchillas, squirrels), or monkeys, etc.

[0059] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.

[0060] Example 1: Effect of Cordyceps sinensis fermented mycelium powder administration on body weight in mice with intestinal radiation injury

[0061] The fermented Cordyceps sinensis mycelium powder was provided by Hangzhou Sino-American East China Pharmaceutical Co., Ltd. (Hangzhou, China). The preparation method can be found in Example 1 of patent CN200710024324.9. The fermented Cordyceps sinensis mycelium powder can be used to prepare pharmaceuticals and / or health products, and can be formulated into different dosage forms such as tablets, capsules, granules, oral liquids, chewable tablets, effervescent tablets, and powders. A Cordyceps sinensis solution is prepared by dispersing the fermented Cordyceps sinensis mycelium powder in physiological saline.

[0062] Physiological saline (0.9%) was purchased from Shandong Kelun Pharmaceutical Co., Ltd. 40Exactor was purchased from Best Theratronics Ltd., Canada; the ROS detection kit was purchased from Shanghai Enzyme-Linked Biotechnology Co., Ltd.; the IL-6 detection kit was purchased from Shanghai Enzyme-Linked Biotechnology Co., Ltd.; and the TNF-α detection kit was purchased from Shanghai Enzyme-Linked Biotechnology Co., Ltd.

[0063] ROS: Reactive oxygen species; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α.

[0064] 1. Experimental animal groups: Male C57BL / 6J mice (6-8 weeks old, 19-21 grams, 6 mice per group) were randomly divided into three groups: blank group, simple irradiation group and Cordyceps sinensis mycelium group.

[0065] 2. Model Building: Using 40 Exactor was used to irradiate the entire abdomen of mice with gamma rays to the abdominal area. The 40Exactor comes with a local irradiation mold, exposing the entire abdomen, with an absorbed dose of 13 Gy and a dose rate of 0.8 Gy / min.

[0066] 3. Administration method and dosage:

[0067] Control group: No irradiation was received. Administration method: normal saline was administered by gavage once a day at 10:00 am for 20 consecutive days. Gavage dose: 200 μL / animal / time.

[0068] Irradiation-only group: Drug administration started on the day of irradiation. Administration method: normal saline was administered by gavage once a day at 10:00 am for 20 consecutive days. Gavage dose: 200 μL / animal / time.

[0069] Cordyceps sinensis fermented mycelium powder group: The administration began on the day of irradiation, and was administered by gavage once a day at 10:00 am. The administration method was as follows: Cordyceps sinensis fermented mycelium powder was dissolved in physiological saline to make a suspension, 10 mg / 100 μL, and the animals were administered the drug by gavage or oral administration; the gavage dose was 200 μL / animal / time.

[0070] 4. Observation indicators: Since mouse body weight is one of the indicators for judging the severity of intestinal radiation injury, i.e., ionizing radiation injury causes a severe decrease in mouse body weight, the initial body weight of each mouse was recorded before irradiation (i.e., day 0), and the body weight of each mouse was recorded after daily administration of the drug via gavage after irradiation.

[0071] 5. Results and Conclusions: The experimental results are shown in Figure 1. Compared with the control group, the body weight of mice in the irradiation-only group was significantly lower after 20 days of irradiation (p<0.001); compared with the irradiation-only group, the body weight of mice in the Cordyceps sinensis mycelium group was significantly higher after 20 days of irradiation (p<0.05). This indicates that Cordyceps sinensis fermentation mycelium can significantly alleviate the damage to mouse body weight caused by ionizing radiation.

[0072] Table 1. Mouse Body Weight (Body weight is the mean within the group, in grams)

[0073] Example 2: Effects of Cordyceps sinensis fermented mycelium powder on the colon of mice with intestinal radiation injury.

[0074] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0075] 2. Observation indicators: Since the length of the mouse colon is one of the indicators for judging the severity of intestinal radiation damage, i.e., ionizing radiation damage causes a significant reduction in the length of the mouse colon, mice were anesthetized with chloral hydrate and euthanized on day 20. The mice were then dissected, and colon tissue was taken for length measurement and comparison.

[0076] 3. Results and Conclusions: The experimental results are shown in Figure 2. Compared with the control group, the colon length of the mice in the simple irradiation group was significantly reduced (p<0.001); compared with the mice in the simple irradiation group, the colon length of the mice in the Cordyceps sinensis mycelium group was significantly increased (p<0.05). It is evident that Cordyceps sinensis fermented mycelium can significantly increase the colon length in mice with intestinal radiation injury and alleviate the damage to colonic tissue caused by ionizing radiation.

[0077] Table 2. Mouse colon length (length is the mean within the group, unit is cm)

[0078] Example 3: Effect of Cordyceps sinensis fermented mycelium powder administration on blood ROS levels in mice with intestinal radiation injury

[0079] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0080] 2. Observation Indicators: Radiation leads to high levels of ROS in cells. Excessive ROS can cause DNA mutations and mitochondrial dysfunction, damaging biomolecules and cells and leading to cell death. Therefore, a ROS detection kit was used to measure ROS levels to detect the effect of Cordyceps sinensis fermentation powder on blood ROS levels. On day 20, mice were anesthetized with chloral hydrate, and blood was collected from the orbital cavity. After centrifugation at 3000g / min for 20 minutes, the supernatant serum was carefully aspirated. The sample was diluted 1:1 with sample diluent and 50 μL was added to each well. 50 μL of diluted standard and 50 μL of the test sample were added to each well. Immediately, 50 μL of biotin-labeled antibody was added. The plate was covered, gently shaken to mix, and incubated at 37°C for 1 hour. The liquid in the wells was discarded, each well was filled with washing buffer, shaken for 30 seconds, the washing buffer was discarded, and the wells were patted dry with absorbent paper. This operation was repeated 3 times. If a plate washer was used, the number of washes was increased by one. Add 80 μL of avidin-HRP to each well, gently vortex to mix, and incubate at 37°C for 30 minutes. Discard the liquid in the wells, fill each well with washing buffer, vortex for 30 seconds, discard the washing buffer, and pat dry with absorbent paper. Repeat this operation 3 times. If using a plate washer, increase the number of washes by one. Add 50 μL each of substrate A and B to each well, gently vortex to mix, and incubate at 37°C for 10 minutes. Avoid light exposure. Remove the microplate and quickly add 50 μL of stop solution. Measure the results immediately after adding the stop solution. Measure the OD value of each well at 450 nm. Plot the absorbance (OD value) on the ordinate (Y) and the corresponding concentration of the analyte standard on the abscissa (X) to create a curve. The concentration of the analyte in the sample can be calculated from the standard curve based on its OD value.

[0081] 3. Results and Conclusions: The experimental results are shown in Figure 3. Compared with the control group, the blood ROS content of the irradiation group was significantly increased (p<0.001); compared with the irradiation group, the blood ROS content of the Cordyceps sinensis powder group was significantly decreased (p<0.001). This indicates that Cordyceps sinensis fermented powder can significantly reduce the blood ROS content in mice with intestinal radiation injury.

[0082] Table 3. ROS levels in mouse blood (values ​​are mean values ​​within groups, unit: U / mL)

[0083] Example 4: Effect of Cordyceps sinensis fermented mycelium powder administration on ROS content in the small intestine of mice with intestinal radiation injury.

[0084] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0085] 2. Observation indicators: On day 20, mice were anesthetized with chloral hydrate and euthanized. The mice were dissected and small intestinal tissue was collected. The tissue was added to an appropriate amount of physiological saline (1 ml of physiological saline was added to 0.1 g of tissue) and crushed. The tissue was centrifuged at 3000 g / min for 20 minutes, and the supernatant was collected. The ROS content was detected using a ROS detection kit. The detection method was the same as in Example 3.

[0086] 3. Results and Conclusions: The experimental results are shown in Figure 4. Compared with the control group, the ROS content in the small intestine of the irradiation group was significantly increased (p<0.001); compared with the irradiation group, the ROS content in the small intestine of the Cordyceps sinensis powder group was significantly decreased (p<0.001). This indicates that Cordyceps sinensis fermented powder can significantly reduce the ROS content in the small intestine of mice with intestinal radiation injury.

[0087] Table 4. ROS content in mouse small intestine (values ​​are mean values ​​within the group, unit: U / mL)

[0088] Example 5: Effect of Cordyceps sinensis fermented mycelium powder administration on blood IL-6 levels in mice with intestinal radiation injury

[0089] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0090] 2. Observation indicators: Since IL-6 is one of the indicators for assessing radiation damage, the IL-6 content was detected using an IL-6 detection kit. On day 20, after anesthetizing mice with chloral hydrate, blood was collected from the orbital cavity, centrifuged at 3000g / min for 20 minutes, and the supernatant serum was carefully aspirated. The detection method was the same as in Example 3.

[0091] 3. Results and Conclusions: The experimental results are shown in Figure 5. Compared with the control group, the IL-6 content in the blood of mice in the irradiation-only group was significantly increased (p<0.001); compared with the irradiation-only group, the IL-6 content in the blood of mice in the Cordyceps sinensis powder group was significantly decreased (p<0.001). This indicates that Cordyceps sinensis fermented powder can significantly reduce the IL-6 content in the blood of mice with intestinal radiation injury.

[0092] Table 5. IL-6 levels in mouse blood (values ​​are mean values ​​within the group, unit: pg / mL)

[0093] Example 6: Effect of Cordyceps sinensis fermented mycelium powder administration on IL-6 content in the small intestine of mice with intestinal radiation injury.

[0094] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0095] 2. Observation indicators: On day 20, mice were anesthetized with chloral hydrate and euthanized. The mice were dissected and small intestinal tissue was collected. The tissue was added to an appropriate amount of physiological saline (1 ml of physiological saline was added to 0.1 g of tissue) and crushed. The mixture was centrifuged at 3000 g / min for 20 minutes, and the supernatant was collected to detect the IL-6 content using an IL-6 detection kit. The detection method was the same as in Example 3.

[0096] 3. Results and Conclusions: The experimental results are shown in Figure 6. Compared with the control group, the IL-6 content in the small intestine of the irradiation group was significantly increased (p<0.001); compared with the irradiation group, the IL-6 content in the small intestine of the Cordyceps sinensis powder group was significantly decreased (p<0.001). This indicates that Cordyceps sinensis fermented powder can significantly reduce the IL-6 content in the small intestine of mice with intestinal radiation injury.

[0097] Table 6. IL-6 content in the small intestine of mice (values ​​are mean values ​​within the group, unit is pg / mL)

[0098] Example 7: Effect of Cordyceps sinensis fermented mycelium powder administration on blood TNF-α levels in mice with intestinal radiation injury

[0099] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0100] 2. Observation indicators: Since TNF-α is one of the indicators for assessing radiation damage, the TNF-α content was detected using a TNF-α detection kit (ELISA, China). On day 20, after anesthetizing mice with chloral hydrate, blood was collected from the orbital cavity, centrifuged at 3000g / min for 20 minutes, and the supernatant serum was carefully aspirated. The detection method was the same as in Example 3.

[0101] 3. Results and Conclusions: The experimental results are shown in Figure 7. Compared with the control group, the blood TNF-α content of the irradiation group was significantly increased (p<0.001); compared with the irradiation group, the blood TNF-α content of the Cordyceps sinensis powder group was significantly decreased (p<0.001). This indicates that Cordyceps sinensis fermented powder can significantly reduce the blood TNF-α content in mice with intestinal radiation injury.

[0102] Table 7. TNF-α levels in mouse blood (values ​​are mean values ​​within the group, unit: pg / mL)

[0103] Example 8: Effect of Cordyceps sinensis fermented mycelium powder administration on TNF-α content in the small intestine of mice with intestinal radiation injury.

[0104] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0105] 2. Observation indicators: On day 20, mice were anesthetized with chloral hydrate and euthanized. The mice were dissected and small intestinal tissue was collected. The tissue was added to an appropriate amount of physiological saline (1 ml of physiological saline was added to 0.1 g of tissue) and crushed. The tissue was centrifuged at 3000 g / min for 20 minutes, and the supernatant was collected to detect the TNF-α content using a TNF-α detection kit. The detection method was the same as in Example 3.

[0106] 3. Results and Conclusions: The experimental results are shown in Figure 8. Compared with the control group, the TNF-α content in the small intestine of the irradiation group was significantly increased (p<0.001); compared with the irradiation group, the TNF-α content in the small intestine of the Cordyceps sinensis powder group was significantly decreased (p<0.001). This indicates that Cordyceps sinensis fermented powder can significantly reduce the TNF-α content in the small intestine of mice with intestinal radiation injury.

[0107] Table 8. TNF-α content in the small intestine of mice (values ​​are mean values ​​within the group, unit: pg / mL)

[0108] Example 9: Effects of Cordyceps sinensis fermented mycelium powder administration on the small intestinal tissue structure of mice with intestinal radiation injury.

[0109] 1. The experimental animal groups, model establishment, and drug administration methods and dosages are the same as in Example 1.

[0110] 2. Observation Indicators: Since the morphology of mouse small intestinal tissue can directly reflect intestinal health, hematoxylin-eosin (HE) staining is the most commonly used staining method in routine pathological slide preparation. Therefore, HE staining was used to stain the small intestinal tissue. On day 20, mice were anesthetized with chloral hydrate and euthanized. The mice were dissected, and the small intestinal tissue was placed in a tissue embedding cassette and immediately immersed in freshly prepared 4% paraformaldehyde solution to denature and coagulate the proteins in the tissue, thereby maintaining the original morphology and structure of the cells. The tissue was then embedded in paraffin and sectioned to a thickness of 6 μm. The tissue was dewaxed twice with xylene for 10 min each time, rehydrated with a series of concentrations of ethanol (100%, 100%, 95%, 95%) for 5 min each gradient, and soaked in distilled water for 2 min. Hematoxylin staining was applied for 5 min, and the excess stain was washed away with distilled water. Differentiation was performed with 1% hydrochloric acid alcohol solution for 1 min, followed by rinsing twice with tap water for 5 min each time. Stain with eosin solution for 2 minutes, then discard excess staining solution and rapidly dehydrate (using 95% ethanol, 95% ethanol, 100% ethanol, 100% ethanol, xylene, xylene) for 5 minutes each. After air drying, mount with neutral resin. Observe the small intestine tissue structure under a microscope.

[0111] 3. Results and Conclusions: The experimental results are shown in Figure 9. Compared with the control group, the intestinal villi of the mice in the simple irradiation group were sparse and fragmented; compared with the simple irradiation group, the intestinal villi of the mice in the Cordyceps sinensis powder group were more compact and intact. It is evident that Cordyceps sinensis fermented powder significantly improves small intestinal tissue damage in mice with intestinal radiation injury.

[0112] In summary, the results indicate that Cordyceps sinensis can significantly improve symptoms caused by intestinal radiation injury, such as weight loss, shortened colon length, increased ROS levels in the blood and / or small intestine, increased inflammation levels in the blood and / or small intestine, and small intestinal tissue damage. It can be used as a health care product or drug for the prevention and treatment of radiation injury, especially intestinal radiation injury.

[0113] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. Use of Cordyceps sinensis in the preparation of products for the prevention and / or treatment of radiation damage.

2. The use according to claim 1, characterized in that, The radiation damage is caused by ionizing radiation.

3. The use according to claim 2, characterized in that, The ionizing radiation mentioned is the ionizing radiation generated by tumor radiotherapy.

4. The use according to claim 3, characterized in that, The ionizing radiation is gamma-ray radiation.

5. The use according to any one of claims 1 to 4, characterized in that, The radiation damage is intestinal type radiation damage.

6. The use according to claim 5, characterized in that, The intestinal radiation injury is characterized by one or more of the following symptoms: weight loss, shortened colon length, elevated blood and / or small intestinal ROS levels, elevated blood and / or small intestinal inflammation levels, and small intestinal tissue damage.

7. The use according to claim 6, characterized in that, The elevated levels of inflammation in the blood and / or small intestine include increased levels of inflammatory immune factors.

8. The use according to claim 7, characterized in that, The inflammatory immune factors are IL-6 and / or TNF-α. Use of 9.4g to 8g unit dose of Cordyceps sinensis in products for the prevention and / or treatment of radiation damage: the unit dose of Cordyceps sinensis is administered once daily.

10. The use according to claim 9, characterized in that, The radiation damage is caused by ionizing radiation.

11. The use according to claim 10, characterized in that, The ionizing radiation mentioned is the ionizing radiation generated by tumor radiotherapy.

12. The use according to claim 11, characterized in that, The ionizing radiation is gamma-ray radiation.

13. The use according to any one of claims 9 to 12, characterized in that, The radiation damage is intestinal type radiation damage.

14. The use according to claim 13, characterized in that, The intestinal radiation injury is characterized by one or more of the following symptoms: weight loss, shortened colon length, elevated blood and / or small intestinal ROS levels, elevated blood and / or small intestinal inflammation levels, and small intestinal tissue damage.

15. The use according to claim 14, characterized in that, The elevated levels of inflammation in the blood and / or small intestine include increased expression of inflammatory immune factors.

16. The use according to claim 15, characterized in that, The inflammatory immune factors are IL-6 and / or TNF-α.

17. The use according to any one of claims 1 to 16, characterized in that, The product in question is a health supplement or a medicine.

18. The use according to any one of claims 1 to 17, characterized in that, Cordyceps sinensis is obtained by artificially fermenting the asexual form of Cordyceps sinensis fungus.

19. The use according to claim 18, characterized in that, The asexual fungus of Cordyceps sinensis is Hirsutella sinensis.

20. The use according to claim 19, characterized in that, The Cordyceps sinensis mentioned is Bailin Capsules.

Images